MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / November ...

In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

As well, Novo Nordisk® has earlier announced a successful outcome of a human trial of 3,533 people with CKD and type 2 diabetes using injected semaglutide. The study 'demonstrated a statistically ...

The two drugs, semaglutide and tirzepatide, are believed to constitute over 90% of all revenue generated in the GLP-1 / GIP sector today. Through the Study, Lexaria is attempting to evidence ...

Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and moreGLP-1 drugs expected to generate multi-hundreds of billions of revenues in the years to come KELOW ...

The two drugs, semaglutide and tirzepatide, are believed to constitute over 90% of all revenue generated in the GLP-1 / GIP sector today. Through the Study, Lexaria is attempting to evidence ...

November 14, 2024--(BUSINESS WIRE)--Olfactive Biosolutions, the leader in harnessing food molecules for the treatment of chronic diseases, has begun production of its Protenx™ GLP-1/GIP Weight ...